Elevated INR in a COVID‐19 patient after concomitant administration of favipiravir and warfarin: A case report
Masao Sekimoto, Toru Imai, Shinji Hidaka, Nobutaka Chiba, Atsushi Sakurai, Mitsumasa Hata, Norikazu Kikuchi
Abstract
WHAT IS KNOWN AND OBJECTIVE: Favipiravir is a promising treatment candidate for managing coronavirus disease 2019 (COVID-19). Warfarin has many drug interactions, but no interactions with favipiravir have been reported. CASE SUMMARY: Our patient was taking warfarin for deep vein thrombosis. The international normalized ratio (INR) was stable (1.65 to 2.0); however, it increased to 4.63 after administering favipiravir. The patient had no other factors justifying this change. WHAT IS NEW AND CONCLUSION: Favipiravir and warfarin might have previously unidentified drug interactions that elevated the INR. Therefore, INR must be closely monitored when they are concomitantly administered in COVID-19 patients.